Dyadic International, Inc. Stock Other OTC
Equities
US26745T1016
Biotechnology & Medical Research
Financials (USD)
Sales 2024 * | 4.2M | Sales 2025 * | 6.1M | Capitalization | 43.56M |
---|---|---|---|---|---|
Net income 2024 * | -22M | Net income 2025 * | -31M | EV / Sales 2024 * | 10.4 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 7.14 x |
P/E ratio 2024 * |
-2.26
x | P/E ratio 2025 * |
-1.66
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 48.27% |
Latest transcript on Dyadic International, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Mark Emalfarb
FOU | Founder | 69 | 78-12-31 |
Ping Rawson
DFI | Director of Finance/CFO | 48 | 16-05-31 |
Joseph Hazelton
COO | Chief Operating Officer | 48 | 21-11-08 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mark Emalfarb
FOU | Founder | 69 | 78-12-31 |
Jack Kaye
BRD | Director/Board Member | 80 | 15-04-30 |
Michael Tarnok
BRD | Director/Board Member | 69 | 14-06-11 |
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.59B | |
+8.57% | 40.65B | |
+49.22% | 40.57B | |
-12.36% | 26.77B | |
+8.92% | 24.81B | |
-25.13% | 18.17B | |
+29.17% | 12.05B | |
-3.12% | 11.7B | |
+6.35% | 11.1B |